Puruisheng was founded in July 2015 and is a high‑tech enterprise originating from the Chinese Academy of Sciences Technical Innovation Research Institute's Precision Targeted Drug Engineering Center. The company focuses on developing novel targeted drugs for precision treatment of tumors. It provides research and technical support services to drug R&D organizations and offers precision medication consulting services to medical institutions. Puruisheng recently completed a new financing round of more than RMB 100 million. Proceeds from the round will be used to accelerate construction of a renewable cancer primary cell biobank (LPCB). The article does not report revenue or user metrics.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2023